Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to <18 Years of Age.
>6 years old - <18 years old
Compensation for time and travel up to
Transportation can be arranged at no cost to you
Study related exams at to cost
TOPAZ Clinical Research 2513 E. Semoran Blvd Apopka, FL 32703